Inflation, Weight Loss Drugs Drive ACA Premiums Higher

Premiums for Affordable Care Act (ACA) health plans will increase 7% on average across 324 insurers next year. This increase is on par with premium increases for 2024, according to Peterson-KFF’s Health System Tracker.

Proposed premium changes for 2025 range from a decrease of 14% to an increase of 51%, although most premium changes fall between 2% and 10% increases for 2025. Fifty of the 324 ACA insurers proposed decreasing premiums, while 85 insurers requested premium increases greater than 10%.

Insurers attributed the increased premiums to growth in health care prices, inflation and the increasing use of weight loss and other specialty drugs.

In most years, medical inflation, the growth in cost and utilization of health care services and medication, outpaces general economic inflation, but through much of 2021 to 2023, inflation in the rest of the economy was so high that it was outpacing growth in medical prices. However, by mid-2024, general economic inflation was cooling, and medical inflation has picked up to the point it now exceeds the growth of non-medical prices.

In their filings with state regulators, some ACA insurers noted general economic inflation has put pressure on their staffing costs as well, increasing their overhead expenses and pushing premiums higher. In addition to the pressure from general economic inflation, hospital market consolidation and workforce shortages are also having an inflationary impact on health insurance premiums in 2025, the tracker found. This has led to increased pricing for services and a willingness to let contracts expire.

The growing demand for GLP-1 drugs like Ozempic and Wegovy, which are used for diabetes treatment and weight loss, is having an upward effect on prescription drug spending. ACA Marketplace insurers employ a variety of strategies including prior authorization, step therapy and quantity limits to manage utilization of Ozempic and other GLP-1s that are approved for diabetes but have potential for off-label use to lose weight. New gene therapies are also becoming more prevalent and more costly, which is driving premiums upward.

Pandemic-related costs and unwinding of Medicaid continuous enrollment beginning in April 2023 are not playing much of a role in ACA premium increases, according to the study. At least 23 million people had been disenrolled from Medicaid as of June 2024, and several million of those had transitioned into the ACA marketplace, but many insurers say the impact on premiums has been negligible. In addition, most insurers say the impact of COVID-19 on their 2025 premiums is zero or near zero, suggesting a steady state relative to the base period.

 

Source Link

Recommended Articles

Hospitals, Clinics Want Nevada To Bolster Protections For Discount Drug Program

Nevada hospitals and health clinics say drug manufacturers are restricting the number of pharmacies in the state that can participate in a federal discount drug program. The limitations put in place by drug companies make it harder for patients to refill prescriptions at reduced rates, and they affect a revenue stream hospitals rely on to ...

Read More

Trump Administration Warns Over 500 Hospitals To Provide More Price Information Or Face Fines

The Trump administration has warned more than 500 hospitals that they are failing to provide the public with basic pricing information — arguing that the lack of disclosure is keeping healthcare costs higher than they should be. The Associated Press obtained exclusively the list of hospitals that since April have either received letters of warning or, in more severe ...

Read More

States Starting To See Major Obamacare Coverage Losses

Newly released state enrollment data show ObamaCare coverage losses could be even more severe than initially anticipated, due to Congress’s unwillingness to renew enhanced subsidies. Monthly enrollment data through April from Arkansas, Colorado, Maryland, Massachusetts, New Mexico and New York showed a significant number of people canceled their coverage or did not pay their premium bills after signing up for coverage in 2026, according to an analysis from Georgetown University. Federal officials have so far only released data ...

Read More

New NFIB Survey: Small Businesses Report Reduced Optimism

The NFIB Small Business Optimism Index fell 0.6 points in May to 95.3, remaining below its 52-year average of 98.0. The Uncertainty Index rose 3 points from April to 91, remaining well above its historical average of 68. As reported in NFIB’s monthly Jobs Report, the NFIB Small Business Employment Index remained essentially flat, registering 100.3 in May. ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square